Olema Pharmaceuticals (OLMA) Competitors $5.29 +0.13 (+2.52%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$5.30 +0.00 (+0.09%) As of 05/1/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OLMA vs. EVO, INDV, OCUL, CALT, AMPH, ARDX, DYN, AUPH, SNDX, and BGMShould you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Evotec (EVO), Indivior (INDV), Ocular Therapeutix (OCUL), Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Dyne Therapeutics (DYN), Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), and Qilian International Holding Group (BGM). These companies are all part of the "pharmaceutical products" industry. Olema Pharmaceuticals vs. Evotec Indivior Ocular Therapeutix Calliditas Therapeutics AB (publ) Amphastar Pharmaceuticals Ardelyx Dyne Therapeutics Aurinia Pharmaceuticals Syndax Pharmaceuticals Qilian International Holding Group Evotec (NASDAQ:EVO) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation. Do analysts rate EVO or OLMA? Evotec presently has a consensus target price of $5.93, indicating a potential upside of 40.27%. Olema Pharmaceuticals has a consensus target price of $27.67, indicating a potential upside of 423.00%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Olema Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, EVO or OLMA? Evotec has higher revenue and earnings than Olema Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$796.97M1.88-$90.82MN/AN/AOlema PharmaceuticalsN/AN/A-$96.65M-$2.21-2.39 Which has more risk and volatility, EVO or OLMA? Evotec has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Is EVO or OLMA more profitable? Evotec's return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets EvotecN/A N/A N/A Olema Pharmaceuticals N/A -53.56%-47.86% Does the media favor EVO or OLMA? In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Olema Pharmaceuticals and 4 mentions for Evotec. Olema Pharmaceuticals' average media sentiment score of 0.87 beat Evotec's score of 0.22 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Olema Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor EVO or OLMA? Olema Pharmaceuticals received 31 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 71.15% of users gave Olema Pharmaceuticals an outperform vote while only 50.00% of users gave Evotec an outperform vote. CompanyUnderperformOutperformEvotecOutperform Votes650.00% Underperform Votes650.00% Olema PharmaceuticalsOutperform Votes3771.15% Underperform Votes1528.85% Do institutionals and insiders believe in EVO or OLMA? 5.8% of Evotec shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Comparatively, 19.4% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryOlema Pharmaceuticals beats Evotec on 10 of the 14 factors compared between the two stocks. Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OLMA vs. The Competition Export to ExcelMetricOlema PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$361.48M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-2.427.3222.5118.54Price / SalesN/A241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book1.156.486.734.25Net Income-$96.65M$143.41M$3.22B$248.18M7 Day Performance7.74%2.58%1.38%1.03%1 Month Performance58.86%5.00%2.79%2.70%1 Year Performance-47.47%-3.72%15.41%4.05% Olema Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OLMAOlema Pharmaceuticals2.4692 of 5 stars$5.29+2.5%$27.67+423.0%-49.1%$361.48MN/A-2.4270Upcoming EarningsEVOEvotec1.8567 of 5 stars$3.58-0.6%$5.93+65.7%-19.4%$1.27B$777.05M0.004,200Upcoming EarningsShort Interest ↓INDVIndivior3.205 of 5 stars$8.81-2.2%$15.00+70.3%-34.5%$1.21B$1.19B-25.171,164Short Interest ↑Positive NewsOCULOcular Therapeutix3.4801 of 5 stars$7.61+4.1%$16.38+115.2%+69.9%$1.21B$63.72M-5.77230Upcoming EarningsNews CoveragePositive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AMPHAmphastar Pharmaceuticals4.4258 of 5 stars$23.50+0.6%$43.50+85.1%-43.3%$1.12B$731.97M7.831,620Upcoming EarningsPositive NewsARDXArdelyx4.5654 of 5 stars$4.56-5.4%$10.61+132.7%-17.2%$1.09B$333.62M-28.5090Earnings ReportNews CoveragePositive NewsDYNDyne Therapeutics3.3267 of 5 stars$9.33+14.2%$47.46+408.7%-53.6%$1.06BN/A-2.62100Short Interest ↑High Trading VolumeAUPHAurinia Pharmaceuticals2.6535 of 5 stars$7.66-1.2%$11.50+50.1%+57.7%$1.05B$235.13M-51.06300Positive NewsSNDXSyndax Pharmaceuticals3.6454 of 5 stars$11.93+3.4%$36.20+203.4%-37.1%$1.03B$23.68M-3.29110Upcoming EarningsPositive NewsBGMQilian International Holding GroupN/A$10.52-4.4%N/AN/A$1.02B$25.10M0.00298 Related Companies and Tools Related Companies EVO Alternatives INDV Alternatives OCUL Alternatives CALT Alternatives AMPH Alternatives ARDX Alternatives DYN Alternatives AUPH Alternatives SNDX Alternatives BGM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OLMA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OLMA Stock Free OLMA Stock Alerts